NORDIC PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
NORDIC PHARMA
Largest movements
- Cash -€224,402
down €224,402 (-63.4%), from €353,968 to €129,566
mainly Receivables within one year (-€211,278) and Stocks and contracts (-€200,412)
- Receivables within one year +€211,278
up €211,278 (+63.7%), from €331,458 to €542,736
- Stocks and contracts +€200,412
up €200,412 (+44.3%), from €452,260 to €652,672
- Profit (loss) carried forward +€387,245
up €387,245 (+39.4%), from -€982,433 to -€595,188
- Accrued charges and deferred income -€105,667
down €105,667 (-66.6%), from €158,672 to €53,005
- Tax, wage and social debts -€52,892
down €52,892 (-77.1%), from €68,628 to €15,736
of which Remuneration and social security: -€60,243
- Debts after one year -€50,000
down €50,000 (-5.3%), from €950,000 to €900,000
- Gross operating margin +€95,331
up €95,331 (+17.3%), from €552,546 to €647,877
- Staff costs -€57,520
down €57,520 (-26.7%), from €215,626 to €158,106
- Write-downs -€24,258
no longer reported in 2025 (was €24,258)
- Other operating charges +€20,460
up €20,460 (+50.0%), from €40,880 to €61,340
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,137,894 | €1,327,631 | +€189,737 | +16.7% |
| Fixed assets | 21/28 | €209 | €209 | = | 0.0% |
| Financial fixed assets | 28 | €209 | €209 | = | 0.0% |
| Current assets | 29/58 | €1,137,685 | €1,327,422 | +€189,737 | +16.7% |
| Stocks and contracts in progress | 3 | €452,260 | €652,672 | +€200,412 | +44.3% |
| Stocks | 30/36 | €452,260 | €652,672 | +€200,412 | +44.3% |
| Amounts receivable within one year | 40/41 | €331,458 | €542,736 | +€211,278 | +63.7% |
| Trade receivables | 40 | €331,458 | €542,736 | +€211,278 | +63.7% |
| Cash at bank and in hand | 54/58 | €353,968 | €129,566 | -€224,402 | -63.4% |
| Deferred charges and accrued income | 490/1 | - | €2,449 | +€2,449 | |
| Total equity and liabilities | 10/49 | €1,137,894 | €1,327,631 | +€189,737 | +16.7% |
| Equity | 10/15 | -€154,433 | €232,812 | +€387,245 | |
| Contributions | 10/11 | €752,727 | €752,727 | = | 0.0% |
| Capital | 10 | €752,727 | €752,727 | = | 0.0% |
| Issued capital | 100 | €752,727 | €752,727 | = | 0.0% |
| Reserves | 13 | €75,273 | €75,273 | = | 0.0% |
| Non-distributable reserves | 130/1 | €75,273 | €75,273 | = | 0.0% |
| Legal reserve | 130 | - | €75,273 | +€75,273 | |
| Reserves not available under the articles | 1311 | €75,273 | - | -€75,273 | |
| Profit (loss) carried forward | 14 | -€982,433 | -€595,188 | +€387,245 | +39.4% |
| Amounts payable | 17/49 | €1,292,327 | €1,094,819 | -€197,508 | -15.3% |
| Amounts payable after more than one year | 17 | €950,000 | €900,000 | -€50,000 | -5.3% |
| Financial debts | 170/4 | €950,000 | €900,000 | -€50,000 | -5.3% |
| Amounts payable within one year | 42/48 | €183,656 | €141,814 | -€41,842 | -22.8% |
| Trade debts | 44 | €115,027 | €126,078 | +€11,051 | +9.6% |
| Suppliers | 440/4 | €115,027 | €126,078 | +€11,051 | +9.6% |
| Taxes, remuneration and social security | 45 | €68,628 | €15,736 | -€52,892 | -77.1% |
| Taxes | 450/3 | €8,385 | €15,736 | +€7,351 | +87.7% |
| Remuneration and social security | 454/9 | €60,243 | - | -€60,243 | |
| Accrued charges and deferred income | 492/3 | €158,672 | €53,005 | -€105,667 | -66.6% |
| Remuneration, social security and pensions | 62 | €215,626 | €158,106 | -€57,520 | -26.7% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €24,258 | - | -€24,258 | |
| Other operating charges | 640/8 | €40,880 | €61,340 | +€20,460 | +50.0% |
| Gross operating margin | 9900 | €552,546 | €647,877 | +€95,331 | +17.3% |
| Operating profit (loss) | 9901 | €271,783 | €428,432 | +€156,648 | +57.6% |
| Financial income | 75/76B | €162 | - | -€162 | |
| Recurring financial income | 75 | €162 | - | -€162 | |
| Financial charges | 65/66B | €42,478 | €40,589 | -€1,889 | -4.4% |
| Recurring financial charges | 65 | €42,478 | €40,589 | -€1,889 | -4.4% |
| Profit (loss) for the period before taxes | 9903 | €229,467 | €387,843 | +€158,376 | +69.0% |
| Income taxes | 67/77 | €764 | €598 | -€166 | -21.7% |
| Profit (loss) for the period | 9904 | €228,703 | €387,245 | +€158,542 | +69.3% |
| Profit (loss) for the period to be appropriated | 9905 | €228,703 | €387,245 | +€158,542 | +69.3% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.